PR
Pandurangan Rajeswari
About Pandurangan Rajeswari
Pandurangan Rajeswari has 16 years in corporate governance. Holds Director role. Currently with 1 company, including Nobel Pharma & Chemicals Private Limited and Glemix Pharma Private Limited. Formerly with 3 companies, such as Lampro Technologies Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Glemix Pharma Private Limited
U24239TN2022PTC152707
|
Director | 30 May 2022 | 2022 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Lampro Technologies Private Limited
U72200TN2010PTC076224
|
Director | 21 Jun 2010 | 2010 | Strike Off |
Nobel Pharma & Chemicals Private Limited
U24200TN2013PTC090599
|
Director | 16 Apr 2013 | 2013 | Strike Off |
Nobel Soft Private Limited
U72900TN2013PTC090816
|
Director | 29 Apr 2013 | 2013 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Pandurangan Rajeswari
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pandurangan Rajeswari
Pandurangan Rajeswari has 16 years in corporate governance. Holds Director role. Currently with 1 company, including Nobel Pharma & Chemicals Private Limited and Glemix Pharma Private Limited. Formerly with 3 companies, such as Lampro Technologies Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Pandurangan Rajeswari is associated with 1 company as Director.
Pandurangan Rajeswari has expertise in General Business, Technology.
Pandurangan Rajeswari has 16 years in corporate governance.